Detalhe da pesquisa
1.
Exposure-Efficacy Analyses Support Optimal Dosing Regimens of Ceftolozane/Tazobactam in Participants with Hospital-Acquired/Ventilator-Associated Bacterial Pneumonia in ASPECT-NP.
Antimicrob Agents Chemother;
66(5): e0139921, 2022 05 17.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35471040
2.
Clinical and microbiological outcomes, by causative pathogen, in the ASPECT-NP randomized, controlled, Phase 3 trial comparing ceftolozane/tazobactam and meropenem for treatment of hospital-acquired/ventilator-associated bacterial pneumonia.
J Antimicrob Chemother;
77(4): 1166-1177, 2022 03 31.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35022730
3.
Molecular Characterization of Baseline Enterobacterales and Pseudomonas aeruginosa Isolates from a Phase 3 Nosocomial Pneumonia (ASPECT-NP) Clinical Trial.
Antimicrob Agents Chemother;
65(3)2021 02 17.
Artigo
em Inglês
| MEDLINE
| ID: mdl-33318005
4.
Ceftolozane/tazobactam probability of target attainment and outcomes in participants with augmented renal clearance from the randomized phase 3 ASPECT-NP trial.
Crit Care;
25(1): 354, 2021 10 02.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34600585
5.
Ceftolozane/tazobactam versus meropenem in patients with ventilated hospital-acquired bacterial pneumonia: subset analysis of the ASPECT-NP randomized, controlled phase 3 trial.
Crit Care;
25(1): 290, 2021 08 11.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34380538
6.
Ceftolozane/Tazobactam in Neonates and Young Infants: The Challenges of Collecting Pharmacokinetics and Safety Data in This Vulnerable Patient Population.
Am J Perinatol;
38(8): 804-809, 2021 07.
Artigo
em Inglês
| MEDLINE
| ID: mdl-31910460
7.
Lung penetration, bronchopulmonary pharmacokinetic/pharmacodynamic profile and safety of 3 g of ceftolozane/tazobactam administered to ventilated, critically ill patients with pneumonia.
J Antimicrob Chemother;
75(6): 1546-1553, 2020 06 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-32211756
8.
Impact of renal impairment and human organic anion transporter inhibition on pharmacokinetics, safety and tolerability of relebactam combined with imipenem and cilastatin.
Br J Clin Pharmacol;
86(5): 944-957, 2020 05.
Artigo
em Inglês
| MEDLINE
| ID: mdl-31856304
9.
Ceftolozane-Tazobactam Population Pharmacokinetics and Dose Selection for Further Clinical Evaluation in Pediatric Patients with Complicated Urinary Tract or Complicated Intra-abdominal Infections.
Antimicrob Agents Chemother;
63(6)2019 06.
Artigo
em Inglês
| MEDLINE
| ID: mdl-30962340
10.
The efficacy and safety of tazobactam/ceftolozane in Japanese patients with uncomplicated pyelonephritis and complicated urinary tract infection.
J Infect Chemother;
25(2): 104-110, 2019 Feb.
Artigo
em Inglês
| MEDLINE
| ID: mdl-30420153
11.
The efficacy and safety of tazobactam/ceftolozane in combination with metronidazole in Japanese patients with complicated intra-abdominal infections.
J Infect Chemother;
25(2): 111-116, 2019 Feb.
Artigo
em Inglês
| MEDLINE
| ID: mdl-30528561
12.
Intrapulmonary Pharmacokinetics of Relebactam, a Novel ß-Lactamase Inhibitor, Dosed in Combination with Imipenem-Cilastatin in Healthy Subjects.
Antimicrob Agents Chemother;
62(3)2018 03.
Artigo
em Inglês
| MEDLINE
| ID: mdl-29311084
13.
Pharmacokinetics, Safety, and Tolerability of Single and Multiple Doses of Relebactam, a ß-Lactamase Inhibitor, in Combination with Imipenem and Cilastatin in Healthy Participants.
Antimicrob Agents Chemother;
62(9)2018 09.
Artigo
em Inglês
| MEDLINE
| ID: mdl-29914955
14.
Chemical Stability of Ceftolozane/Tazobactam in Polyvinylchloride Bags and Elastomeric Pumps.
Curr Ther Res Clin Exp;
84: 22-25, 2017.
Artigo
em Inglês
| MEDLINE
| ID: mdl-28761575
15.
Raltegravir has a low propensity to cause clinical drug interactions through inhibition of major drug transporters: an in vitro evaluation.
Antimicrob Agents Chemother;
58(3): 1294-301, 2014.
Artigo
em Inglês
| MEDLINE
| ID: mdl-24295974
16.
Erratum for Rhee et al., "Pharmacokinetics, Safety, and Tolerability of Single and Multiple Doses of Relebactam, a ß-Lactamase Inhibitor, in Combination with Imipenem and Cilastatin in Healthy Participants".
Antimicrob Agents Chemother;
62(12)2018 12.
Artigo
em Inglês
| MEDLINE
| ID: mdl-30478180
17.
Adenovirus serotype 26 utilizes CD46 as a primary cellular receptor and only transiently activates T lymphocytes following vaccination of rhesus monkeys.
J Virol;
86(19): 10862-5, 2012 Oct.
Artigo
em Inglês
| MEDLINE
| ID: mdl-22811531
18.
Probability of Target Attainment Analyses to Inform Ceftolozane/Tazobactam Dosing Regimens for Patients With Hospital-Acquired or Ventilator-Associated Bacterial Pneumonia and End-Stage Renal Disease Receiving Intermittent Hemodialysis.
J Clin Pharmacol;
63(2): 166-171, 2023 02.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36046982
19.
Safety and Efficacy of Ceftolozane/Tazobactam Versus Meropenem in Neonates and Children With Complicated Urinary Tract Infection, Including Pyelonephritis: A Phase 2, Randomized Clinical Trial.
Pediatr Infect Dis J;
42(4): 292-298, 2023 04 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36689671
20.
Safety and Efficacy of Ceftolozane/Tazobactam Plus Metronidazole Versus Meropenem From a Phase 2, Randomized Clinical Trial in Pediatric Participants With Complicated Intra-abdominal Infection.
Pediatr Infect Dis J;
42(7): 557-563, 2023 Jul 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37000942